IDEAYA Biosciences, Inc.
IDYA
$24.12
-$0.88-3.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.00M | 7.00M | 3.92M | 11.96M | 15.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00M | 7.00M | 3.92M | 11.96M | 15.50M |
| Cost of Revenue | 322.75M | 294.67M | 193.26M | 169.81M | 144.45M |
| Gross Profit | -315.75M | -287.67M | -189.34M | -157.85M | -128.95M |
| SG&A Expenses | 44.59M | 39.30M | 35.42M | 33.54M | 30.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 367.35M | 333.98M | 228.68M | 203.35M | 174.67M |
| Operating Income | -360.35M | -326.98M | -224.75M | -191.39M | -159.17M |
| Income Before Tax | -307.08M | -274.48M | -178.12M | -153.74M | -128.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -307.08 | -274.48 | -178.12 | -153.74 | -128.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -307.08M | -274.48M | -178.12M | -153.74M | -128.89M |
| EBIT | -360.35M | -326.98M | -224.75M | -191.39M | -159.17M |
| EBITDA | -357.98M | -324.59M | -222.31M | -188.88M | -156.67M |
| EPS Basic | -3.59 | -3.30 | -2.33 | -2.18 | -2.00 |
| Normalized Basic EPS | -2.41 | -2.23 | -1.56 | -1.47 | -1.36 |
| EPS Diluted | -3.59 | -3.30 | -2.33 | -2.18 | -2.00 |
| Normalized Diluted EPS | -2.41 | -2.23 | -1.56 | -1.47 | -1.36 |
| Average Basic Shares Outstanding | 339.85M | 326.60M | 304.51M | 278.32M | 256.61M |
| Average Diluted Shares Outstanding | 339.85M | 326.60M | 304.51M | 278.32M | 256.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |